Avacta

Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.

[Avacta @avacta]

In this Episode of the R&D Spotlight Series, the team discuss the key findings from our ESMO data.  One important finding is that tumors recruit fibroblasts during treatment, leading to an increased ability to release the payload. 

https://t.co/DLG6qEo9Ww #AVCT

[Avacta @avacta]

Avacta will present AVA6207, its Next-Generation pre|CISION® dual payload peptide-drug conjugate, in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18-20. https://t.co/9dVUvSOJLO #AVCT

[Avacta @avacta]

Our CEO Christina Coughlin participating in the Prioritizing the Pipeline panel with @LongwoodLeaders in Boston today, discussing how we assess our platform opportunities to deliver high patient impact. #AVCT https://t.co/eP1XCtWUfn

[Avacta @avacta]

CEO Christina Coughlin and CFO Brian Hahn will be at @Jefferies Healthcare Conference, Nov 16-19 in London. Curious how pre|CISION® keeps potent payloads silent in the bloodstream and active in the tumor? Book a 1:1 via the partnering system. https://t.co/PoHwBYBgkM #AVCT

[Avacta @avacta]

Watch the latest episode of our R&D Spotlight series. In the second of Avacta Chief Executive Officer @coughlin582’s deep dives into the data presented at ESMO 2026, the focus is today on AVA6000. https://t.co/Epyt8ez8Mb #AVCT

[Avacta @avacta]

Watch episode 16 of our R&D Spotlight series, where Avacta Chief Executive Officer @coughlin582 takes a deep dive into the AVA6103 data presented at ESMO 2026. https://t.co/Sm4KYcdPzG #AVCT

[Avacta @avacta]

New at #ESMO26: faridoxorubicin (AVA6000) data in salivary gland cancers show a median PFS of 11.4 months, with FAPI-PET imaging showing FAP persists as tumors respond. Poster 1549P, 12:00-12:45 PM CET.
https://t.co/lhnwd6E0Ol
#preCISION #AVCT

[Avacta @avacta]

At #ESMO26, we’re presenting the FOCUS-01 trial design and new preclinical data for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, including activity in Enhertu®-resistant tumor models.
https://t.co/89dfmPg6j7 #preCISION #NextGenLoading #AVCT

[Avacta @avacta]

Avacta will present the most recent data analysis from the ongoing Phase 1a trial of Faridoxorubicin (AVA6000) and the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the ESMO 2026 Congress. https://t.co/O3a0xufNqB #AVCT

[Avacta @avacta]

Christina Coughlin, CEO, and Brian Hahn, CFO, will provide a live presentation relating to the Interim Results via Investor Meet Company on 15 Oct 2026, 16:00 BST. https://t.co/0tsTgIl4uH #AVCT

[Avacta @avacta]

Avacta today publishes its unaudited interim results for the six months ended June 30, 2026. https://t.co/O9avvX9Tmm #AVCT

[Avacta @avacta]

Avacta's pre|CISION® platform has been honored by the Pharma Industry Awards UK 2026, winning the Research and Development Achievement Award. https://t.co/nIVZap0fBg #AVCT

[Avacta @avacta]

We’re presenting the FOCUS-01 trial design and new preclinical data for AVA6103 (FAP-Exd) at the AACR Conference on Pancreatic Cancer.

https://t.co/baUM7yaam8

#PancreaticCancer #preCISION #AVCT #NextGenLoading

[Avacta @avacta]

Ask a scientist why they stay in oncology and you will usually hear about a "wow moment". The people behind pre|CISION® share theirs, from the first tumor to plasma data to a new molecule from idea to IND in 12 months. Watch the video here: https://t.co/yQYPRuyU6Y #AVCT

[Avacta @avacta]

In episode 16 of the R&D Spotlight, the team discusses initial clinical data for AVA6103, pre|CISION® controlled-release exatecan, with two key clinical findings demonstrating proof of mechanism.

https://t.co/eDiCI7vNc6 #NextGenLoading #AVCT

[Avacta @avacta]

We have achieved clinical proof of mechanism for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, in the Phase 1 FOCUS-01 trial. Clean safety profile through 3 dose levels, and clinical PK closely matches preclinical modeling.
https://t.co/IbI1P3XUPy
#NextGenLoading #AVCT

[Avacta @avacta]

Avacta today announced the appointment of the seasoned biotech executive Mr. Mats Blom as a member of its Board of Directors and Chair of the Audit Committee. https://t.co/Ii54pm5io3 #AVCT

[Avacta @avacta]

Avacta announces that it has received an accelerated payment notice from the convertible bond holder in respect of the April 2026 quarterly deferred convertible bond repayment, which the Company has elected to settle in cash. https://t.co/mPwGfkN5MX #AVCT

[Avacta @avacta]

Share Option Awards to Management Team at Avacta. https://t.co/UB2iElPiET #AVCT

[Avacta @avacta]

Avacta Academy, Episode 5: Taking a New Drug to the Clinic, Bench to Bedside.

Meet the Avacta clinical team and hear how a medicine travels from the bench, through the IND and into the clinic, then back to the bench to shape the next candidate.
https://t.co/vTztthTh8G #AVCT